Evidence map›Paper›PMID 25300552›Full record

ArticleLangmuir : the ACS journal of surfaces and colloids2014

Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs.

Olga B Garbuzenko, Jennifer Winkler, M Silvina Tomassone, Tamara Minko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Langmuir : the ACS journal of surfaces and colloids, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Curcumin: reclaiming the lost ground against cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  20. Janus particles: recent advances in the biomedical applications.International journal of nanomedicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Olga B GarbuzenkoDepartment of Pharmaceutics, Rutgers, The State University of New Jersey University , 160 Frelinghuysen Rd., Piscataway, New Jersey 08854, United States.
Jennifer Winkler
M Silvina Tomassone
Tamara Minko
Rutgers, The State University of New Jersey · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Shridar Ganesan · 1997 to 2026
$94.5M
Nanotechnology Approach for Inhalation Treatment of Pulmonary FibrosisR01HL118312 · NHLBI · RUTGERS, THE STATE UNIV OF N.J. · PI MINKO, TAMARA · 2014 to 2017
$1.9M
Molecular Targeting of Drug Delivery System to CancerR01CA111766 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI MINKO, TAMARA · 2006 to 2010
$1.3M
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA111766NHLBI NIH HHS R01 HL118312
6 · The paper itself

Abstract

The aim of the present work is to synthesize, characterize, and test self-assembled anisotropic or Janus particles designed to load anticancer drugs for lung cancer treatment by inhalation. The particles were synthesized using binary mixtures of biodegradable and biocompatible materials. The particles did not demonstrate cyto- and genotoxic effects. Janus particles were internalized by cancer cells and accumulated both in the cytoplasm and nuclei. After inhalation delivery, nanoparticles accumulated preferentially in the lungs of mice and retained there for at least 24 h. Two drugs or other biologically active components with substantially different aqueous solubility can be simultaneously loaded in two-phases (polymer-lipid) of these nanoparticles. In the present proof-of-concept investigation, the particles were loaded with two anticancer drugs: doxorubicin and curcumin as model anticancer drugs with relatively high and low aqueous solubility, respectively. However, there are no obstacles for loading any hydrophobic or hydrophilic chemical agents. Nanoparticles with dual load were used for their local inhalation delivery directly to the lungs of mice with orthotopic model of human lung cancer. In vivo experiments showed that the selected nanoparticles with two anticancer drugs with different mechanisms of action prevented progression of lung tumors. It should be stressed that anticancer effects of the combined treatment with two anticancer drugs loaded in the same nanoparticle significantly exceeded the effect of either drug loaded in similar nanoparticles alone.

Indexed as

Hydrophobic and Hydrophilic InteractionsAdministration, InhalationAnimalsAnisotropyAntineoplastic AgentsBiological TransportCell Line, TumorCurcuminDoxorubicinDrug CarriersHumansLungMiceMutagenicity TestsNanoparticlesParticle SizeAntineoplastic AgentsCurcuminDoxorubicinDrug Carriers

Identifiers

PMID25300552
PMCPMC4222657
OpenAlexW1968909368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.